GlassScriptPhysician profile
Joshiah Gordon
NPI 1952454290
$207,850.90
in general payments reported to CMS, 2019-2025
26 companies · $42K in 2025
The $42K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $24K · 2021: $20K · 2022: $17K · 2023: $14K · 2024: $33K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $7,310 · Travel and Lodging: $7,308 · Education: $4,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,455.00 |
| Food and Beverage | $7,309.74 |
| Travel and Lodging | $7,308.20 |
| Education | $4,021.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $112,663.70 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Actelion Pharmaceuticals US, INC. | $32,205.17 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Grifols USA, LLC | $26,218.09 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $15,339.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $8,881.10 | 2019-2022 | |
| Intuitive Surgical, INC. | $6,490.80 | 2025 | |
| Medtronic, INC. | $1,540.00 | 2022 | |
| Pulmonx Corporation | $1,078.08 | 2020-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Mylan Specialty L.P. | $870.00 | 2020 | |
| Grifols Shared Services North America, INC. | $799.17 | 2023-2025 | Prolastin-C Liquid |
| Olympus Corporation of The Americas | $510.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $270.44 | 2022-2024 | Tezspire, Breztri, Imfinzi |
| Glaxosmithkline, LLC. | $217.34 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $172.50 | 2022-2025 | Dupixent |
| Philips North America LLC | $127.65 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $110.11 | 2021-2024 | |
| Genentech USA, INC. | $99.99 | 2019 | |
| Veran Medical Technologies, INC. | $89.14 | 2019 | |
| Astellas Pharma US INC | $34.19 | 2024 | Cresemba |
| Ani Pharmaceuticals, INC. | $27.49 | 2023 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $21.42 | 2023 | Coredx |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Olympus America INC. | $17.79 | 2021 | |
| Sandoz INC. | $15.96 | 2024 | Treprostinil |
| Biogen, INC. | $15.42 | 2024 | Spinraza |
| Resmed Corp | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshiah Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.